Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Brief Summary:

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of romidepsin and oral azacytidine to single agent drugs already determined effective in patients with PTCL. For the purposes of this study, the single agent drugs already used to treat lymphoma are called investigator's choice (IC), meaning the investigator will choose which one of these drugs to administer. The IC drug options include romidepsin, belinostat, pralatrexate or gemcitabine given alone. Funding Source: FDA OOPD.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/ct2/show/NCT04747236?term=NCT04747236&draw=2&rank=1

Sponsor: University of Virginia

Collaborator: Celgene

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04747236 

Contact: Enrica Marchi, MD 434-924-9637 em5yt@hscmail.mcc.virginia.edu

Contact: Marian Abdelmalek, MS 434-924-8827 mka6s@hscmail.mcc.virginia.edu


Participating Locations:

Emily Couric Clinical Cancer Center
Charlottesville, VA, United States
Principal Investigator
Enrica Marchi, MD
Marian Abdelmalek, MS